Akari Therapeutics Plc
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
AKTX$7.66+3.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(amounts in thousands, except share and per share data)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash | $2,484 | $2,599 |
| Restricted cash | 60 | 60 |
| Prepaid expenses | 349 | 92 |
| Other current assets | 53 | 201 |
| Total current assets | 2,946 | 2,952 |
| Goodwill | 8,430 | 8,430 |
| Other intangible assets | 34,000 | 39,180 |
| Total assets | $45,376 | $50,562 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $10,844 | $12,407 |
| Accrued expenses | 1,623 | 3,137 |
| Convertible notes, net | 663 | 700 |
| Convertible notes - related party | — | 250 |
| Notes payable, net | 198 | 659 |
| Notes payable - related party, net | 1,256 | 1,651 |
| Warrant liabilities | 503 | 1,012 |
| Other current liabilities | 481 | 94 |
| Total current liabilities | 15,568 | 19,910 |
| Derivative liability | 100 | — |
| Other non-current liabilities | 69 | 383 |
| Deferred tax liability | 6,952 | 8,040 |
| Total liabilities | 22,689 | 28,333 |
| Commitments and contingencies (Note 14) | - | - |
| Shareholders’ equity: | ||
| Share capital of $0.0001 par value | ||
| Authorized: 330,854,276,210 and 245,035,791,523 Ordinary Shares at September 30, 2025 and December 31, 2024, respectively; issued and outstanding: 65,229,461,523 and 53,186,919,523 Ordinary Shares at September 30, 2025 and December 31, 2024, respectively | 6,523 | 5,319 |
| Additional paid-in capital | 224,366 | 212,706 |
| Capital redemption reserve | 52,194 | 52,194 |
| Accumulated other comprehensive loss | (1,144) | (738) |
| Accumulated deficit | (259,252) | (247,252) |
| Total shareholders’ equity | 22,687 | 22,229 |
| Total liabilities and shareholders’ equity | $45,376 | $50,562 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.